Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2020-08-27 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo announcing the publication of final results from the DRIIV Phase 1 clinical study in the British Journal of Cancer. It details clinical trial outcomes, safety profiles, optimal dosing, and future study plans (DRIIV-1b and REVOCAN). This content is characteristic of an announcement regarding clinical/research progress, which often accompanies or precedes a formal financial filing, but the primary nature here is the dissemination of scientific/clinical news to the market. Since it is a formal announcement of results and progress, and not a full financial report (10-K, IR) or a transcript (CT), it fits best under the category of general corporate/regulatory news dissemination. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant corporate news that isn't explicitly covered by ER, IR, or AR, although it strongly resembles an Investor Presentation (IP) in its detailed nature. However, because it is explicitly framed as an 'annonce' (announcement) of a publication, and not the presentation itself, RNS (Regulatory Filings/General Announcement) is the safest classification, as it is a broad category for important corporate updates not fitting elsewhere. It is not a standard Earnings Release (ER) as it focuses on clinical data, not quarterly financials.
2020-08-27 French
Inside Information / Other news releases
Delisting Announcement Classification · 1% confidence The document is a press release dated July 29, 2020, announcing the decision by Onxeo S.A. to transfer the listing of its securities from the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading facility. This announcement details the rationale, shareholder approval, regulatory consequences (including changes to periodic financial information disclosure and minority shareholder protection), and an indicative timetable for the transfer. While it mentions future reports (Annual Report, Half-Year Report) and director obligations (MAR art. 19, related to insider trading/DIRs), the primary subject is the corporate action of changing listing venues. This type of announcement, which concerns a significant structural/regulatory change but doesn't fit neatly into standard financial reports (10-K, IR, ER) or specific corporate actions like dividends or M&A, is best classified as a general Regulatory Filing or Announcement. Since it is a specific announcement about a regulatory/listing change, and not a general 'Regulatory Filing' fallback, I must check if there is a better fit. It is not a Delisting Announcement (DLST) because it is a *transfer* to another market (Euronext Growth Paris), not a complete removal from trading. It is not a Director's Dealing (DIRS) or Major Shareholding (MRQ). Given the nature of the announcement—a formal notice regarding a change in listing venue and associated regulatory adjustments—it falls under the broad category of significant corporate news that must be disclosed to the market. Since there is no specific code for 'Listing Change Announcement', and it is a formal communication about regulatory compliance and market structure, the most appropriate classification among the provided options is RNS (Regulatory Filings), which serves as the general regulatory announcement category.
2020-07-29 English
Informations privilégiées / Autres communiqués
Delisting Announcement Classification · 1% confidence The document is a press release dated July 29, 2020, announcing the Board of Directors' decision to transfer the company's listing from the regulated market Euronext Paris (Compartment C) to the multilateral trading facility Euronext Growth Paris. It details the rationale, shareholder approval, timeline for the transfer, and discusses the implications for periodic financial reporting (Annual Report, Half-Year Report) and ongoing information requirements under MAR. Crucially, it contains a specific future announcement: "Onxeo publiera son Rapport financier semestriel 2020 le 17 septembre 2020." Since this document is an announcement about a corporate action (listing transfer) and provides context/timelines rather than being the comprehensive financial report itself, it does not fit 10-K or IR. It is a general corporate announcement regarding regulatory/listing status. While it mentions future reports, the primary focus is the listing change. This type of significant corporate action announcement, which doesn't fit neatly into specific financial event codes (like DIV, CAP, M&A), is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) due to the listing change affecting capital structure visibility. Given the broad nature of the announcement covering listing rules, shareholder protection, and future reporting changes, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fallback, although it is a very specific corporate action announcement. Since there is no specific code for 'Listing Transfer Announcement', RNS is the best fit among the provided options for a significant, non-standard regulatory communication.
2020-07-29 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Regulatory Filings Classification · 1% confidence The document is titled "SUMMARY OF ONXEO'S LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX" and details the shares and cash held in the liquidity account as of June 30, 2020, along with transaction volumes for the first half of 2020 and a comparison to the previous half-year. This content specifically relates to the management of the company's own shares (share repurchase/issuance activities) under a liquidity agreement, which is governed by AMF regulations. This aligns directly with the definition for 'Transaction in Own Shares' (POS), which covers share repurchase/issuance reports. It is not a general earnings release (ER), a full annual report (10-K), or a management discussion (MDA), but a specific report on share transactions related to market making/liquidity provision.
2020-07-03 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Management Reports Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its main subject is the "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC KEPLER CHEUVREUX" (Half-yearly balance sheet of the liquidity contract with Kepler Cheuvreux), dated July 3, 2020, reporting data as of June 30, 2020. This document details the status and trading activity under a liquidity contract over the first half of 2020. This type of periodic disclosure regarding market operations, often mandated by regulators (like the AMF mentioned), is a specific type of regulatory announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a comprehensive Interim Report (IR). Since it is a specific, periodic disclosure related to market stability/liquidity management, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it contains the substance of the report (the balance sheet data) rather than just announcing that a report is available.
2020-07-03 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated June 25, 2020, announcing preclinical confirmation of a drug candidate (OX401) profile, detailing its mechanism of action (PARP agonist, cGAS-STING pathway activation), and providing updates on other company assets (AsiDNA™). It includes quotes from the Chief Scientific Officer and standard sections like 'About Onxeo' and 'Forward-Looking Statements'. This content structure is typical of an announcement regarding scientific/pipeline progress, which is generally classified as an Investor Presentation (IP) if it's detailed, or sometimes an Earnings Release (ER) if it coincides with financial reporting, or a Regulatory Filing (RNS) if it's a mandatory disclosure. Since this is a detailed scientific update focused on pipeline progress and strategy, and not a formal financial report (10-K, IR) or a brief earnings highlight (ER), 'Investor Presentation' (IP) is the most fitting category for detailed pipeline news shared with investors, even though it's formatted as a press release. It is not a short announcement of a report being available (RPA/RNS).
2020-06-25 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.